120 related articles for article (PubMed ID: 30642787)
1. Myocardial hypertrophy induced by high salt consumption is prevented by angiotensin II AT2 receptor agonist.
Dopona EPB; Rocha VF; Furukawa LNS; Oliveira IB; Heimann JC
Nutr Metab Cardiovasc Dis; 2019 Mar; 29(3):301-305. PubMed ID: 30642787
[TBL] [Abstract][Full Text] [Related]
2. Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Ferreira DN; Katayama IA; Oliveira IB; Rosa KT; Furukawa LN; Coelho MS; Casarini DE; Heimann JC
J Nutr; 2010 Oct; 140(10):1742-51. PubMed ID: 20724490
[TBL] [Abstract][Full Text] [Related]
3. High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
Katayama IA; Pereira RC; Dopona EP; Shimizu MH; Furukawa LN; Oliveira IB; Heimann JC
J Nutr; 2014 Oct; 144(10):1571-8. PubMed ID: 25122644
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Castoldi G; Carletti R; Ippolito S; Stella A; Zerbini G; Pelucchi S; Zatti G; di Gioia CRT
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948475
[TBL] [Abstract][Full Text] [Related]
5. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Liang B; Leenen FH
J Cardiovasc Pharmacol; 2008 May; 51(5):457-66. PubMed ID: 18418273
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Bruce E; Shenoy V; Rathinasabapathy A; Espejo A; Horowitz A; Oswalt A; Francis J; Nair A; Unger T; Raizada MK; Steckelings UM; Sumners C; Katovich MJ
Br J Pharmacol; 2015 May; 172(9):2219-31. PubMed ID: 25522140
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats.
Ali Q; Patel S; Hussain T
Am J Physiol Renal Physiol; 2015 Jun; 308(12):F1379-85. PubMed ID: 25855512
[TBL] [Abstract][Full Text] [Related]
8. Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Castoldi G; di Gioia CRT; Roma F; Carletti R; Manzoni G; Stella A; Zerbini G; Perseghin G
Acta Diabetol; 2019 Jan; 56(1):97-104. PubMed ID: 30187136
[TBL] [Abstract][Full Text] [Related]
9. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats.
Louhelainen M; Merasto S; Finckenberg P; Vahtola E; Kaheinen P; Leskinen H; Levijoki J; Pollesello P; Haikala H; Mervaala EM
J Physiol Pharmacol; 2009 Sep; 60(3):41-7. PubMed ID: 19826180
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Biala A; Finckenberg P; Korpi A; Loytainen M; Martonen E; Levijoki J; Mervaala E
J Physiol Pharmacol; 2011 Jun; 62(3):275-85. PubMed ID: 21893687
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of valsartan in mice with short-term high-salt diet by regulating cardiac aquaporin 1 and angiogenic factor expression.
Jiang Y; Wang HY; Zheng S; Mu SQ; Ma MN; Xie X; Zhang YY; Zhang CX; Cai JH
Cardiovasc Pathol; 2015; 24(4):224-9. PubMed ID: 25659450
[TBL] [Abstract][Full Text] [Related]
12. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
[TBL] [Abstract][Full Text] [Related]
13. Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA/NaCl-Induced Hypertension in Female Rats.
Dai SY; Zhang YP; Peng W; Shen Y; He JJ
Oxid Med Cell Longev; 2016; 2016():3981790. PubMed ID: 26783414
[TBL] [Abstract][Full Text] [Related]
14. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome.
Hattori T; Murase T; Takatsu M; Nagasawa K; Matsuura N; Watanabe S; Murohara T; Nagata K
J Am Heart Assoc; 2014 Dec; 3(6):e001312. PubMed ID: 25468654
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
[TBL] [Abstract][Full Text] [Related]
16. Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats.
Dai SY; Peng W; Zhang YP; Li JD; Shen Y; Sun XF
J Neuroinflammation; 2015 Mar; 12():47. PubMed ID: 25885968
[TBL] [Abstract][Full Text] [Related]
17. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone.
Lal A; Veinot JP; Leenen FH
Am J Hypertens; 2003 Apr; 16(4):319-23. PubMed ID: 12670750
[TBL] [Abstract][Full Text] [Related]
18. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.
D'Amore A; Black MJ; Thomas WG
Hypertension; 2005 Dec; 46(6):1347-54. PubMed ID: 16286564
[TBL] [Abstract][Full Text] [Related]
19. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage.
Altara R; da Silva GJJ; Frisk M; Spelta F; Zouein FA; Louch WE; Booz GW; Cataliotti A
Hypertension; 2020 May; 75(5):1195-1204. PubMed ID: 32200677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
